Beam Therapeutics Inc. (BEAM)
Largest Insider Buys in Sector
BEAM Stock Price History Chart
BEAM Stock Performance
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Activity of Beam Therapeutics Inc.
Over the last 12 months, insiders at Beam Therapeutics Inc. have bought $0 and sold $38.58M worth of Beam Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Beam Therapeutics Inc. have bought $0 and sold $20.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
List of Insider Buy and Sell Transactions, Beam Therapeutics Inc.
| 2025-01-02 | Sale | Chief Legal Officer | 1,241 0.0015% | $24.68 | $30,628 | -1.17% | ||
| 2025-01-02 | Sale | SVP, Finance and Treasurer | 1,117 0.0014% | $24.68 | $27,568 | -1.17% | ||
| 2024-11-06 | Sale | President | 51,110 0.0594% | $26.36 | $1.35M | -0.98% | ||
| 2024-10-14 | Sale | President | 51,110 0.0592% | $26.27 | $1.34M | -3.38% | ||
| 2024-10-01 | Sale | Chief Legal Officer | 385 0.0004% | $23.48 | $9,040 | +8.03% | ||
| 2024-10-01 | Sale | SVP, Finance and Treasurer | 289 0.0003% | $23.48 | $6,785 | +8.03% | ||
| 2024-09-30 | Sale | CEO | 60,000 0.0651% | $24.60 | $1.48M | +3.18% | ||
| 2024-07-02 | Sale | Chief Medical Officer | 748 0.0008% | $22.95 | $17,167 | +12.12% | ||
| 2024-07-01 | Sale | Chief Medical Officer | 502 0.0005% | $23.76 | $11,928 | +9.72% | ||
| 2024-06-27 | Sale | CEO | 60,000 0.0649% | $24.50 | $1.47M | +5.38% | ||
| 2024-04-02 | Sale | Chief Medical Officer | 16,530 0.0223% | $30.54 | $504,851 | -19.15% | ||
| 2024-04-01 | Sale | CEO | 18,102 0.0257% | $32.13 | $581,617 | -24.34% | ||
| 2024-04-01 | Sale | President | 4,534 0.0064% | $32.12 | $145,632 | -24.34% | ||
| 2024-04-01 | Sale | Chief Legal Officer | 3,401 0.0048% | $32.12 | $109,240 | -24.34% | ||
| 2024-04-01 | Sale | Chief Medical Officer | 7,157 0.0101% | $32.13 | $229,954 | -24.34% | ||
| 2024-04-01 | Sale | Chief Financial Officer | 5,446 0.0077% | $32.12 | $174,926 | -24.34% | ||
| 2024-03-28 | Sale | CEO | 60,000 0.0896% | $33.86 | $2.03M | -25.18% | ||
| 2024-02-14 | Sale | See Remark 1 | 900,000 1.2132% | $30.55 | $27.5M | -19.94% | ||
| 2024-02-13 | Sale | See Remark 1 | 1,565 0.0021% | $30.76 | $48,139 | -16.33% | ||
| 2024-01-31 | Sale | CEO | 60,000 0.0671% | $25.33 | $1.52M | +3.77% |